RELIEF THERAPEUTICS Holding SA positions itself in biotech with a focus on healthcare and rare-disease therapeutics, as indicated in its LinkedIn post. The company announced it secured a CHF 50 million capital commitment from GEM through the renewal of its share subscription facility. The transaction is presented as a renewal of an existing share subscription facility rather than a newly announced equity round. The LinkedIn post included the company tickers $RLF $RLFTF $RLFTY and used hashtags referencing biotech, healthcare, and rare disease. Social-media commenters raised questions about whether a proposed 400:1 reverse share split and plans to list on Nasdaq were affected by the news. The post did not disclose operating metrics, valuation, past financing rounds, founding year, or location. Relief Therapeutics is a clinical-stage biotechnology company focused on developing treatments for conditions associated with degeneration of the peripheral nervous system (neuropathy). Its lead drug candidate is atexakin alfa. The company intends to use newly raised funds to support clinical development activities for atexakin alfa. Relief secured rights to the underlying intellectual property and global commercialization from Merck KGaA via a licensing agreement dated August 2015. The company is led by CEO Gaël Hédou, COO Michel Dreano, and CSO Yves Sagot, and was incorporated in May 2013 in Geneva, Switzerland. Financially, Relief has begun its €2.5M Series A with receipt of the first tranche from Global Emerging Markets.

Total raised

$60M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2024